Status:

RECRUITING

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Lead Sponsor:

Corbus Pharmaceuticals Inc.

Collaborating Sponsors:

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Conditions:

Solid Tumor, Adult

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answe...

Detailed Description

This is a three-part open-label, Phase 1/2 clinical trial designed to evaluate the safety, PK, and efficacy of CRB-701 in participants with advanced solid tumors expressing nectin-4. Part A will incl...

Eligibility Criteria

Inclusion

  • Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed having exhausted all appropriate lines of therapy or have no other standard therapy with proven clinical benefit. In Part C, HNSCC participants may enroll as first-line therapy.

Exclusion

  • Active of uncontrolled CNS metastases
  • History of solid tumors other than the diseases under study
  • History of and/or current cardiovascular events or conditions in the previous 6 months
  • Pre-existing \>/= Grade 2 neuropathy
  • Hemoglobin A1C (HbA1C) \>/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy
  • Active ocular disease at baseline
  • Chronic severe liver disease or live cirrhosis
  • Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study
  • Other significant cormorbidities.

Key Trial Info

Start Date :

April 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 27 2027

Estimated Enrollment :

348 Patients enrolled

Trial Details

Trial ID

NCT06265727

Start Date

April 1 2024

End Date

January 27 2027

Last Update

January 8 2026

Active Locations (41)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (41 locations)

1

O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham

Birmingham, Alabama, United States, 35294

2

City of Hope Cancer Center

Duarte, California, United States, 91010

3

Moores Cancer Centre at UC San Diego Health

San Diego, California, United States, 92037

4

Helen Diller Family Comprehensive Cancer Center - UCSF

San Francisco, California, United States, 94115